Immunotherapy combinations in the first-line treatment of metastatic sarcomatoid kidney cancer

A recent study looked at the efficacy and safety of first-line treatment with a combination of immunotherapies (immune checkpoint inhibitors) for sarcomatoid renal cell carcinoma (RCC). The analysis included five clinical trials involving 568 patients with sarcomatoid RCC. All combinations that were looked at significantly improved progression-free survival and response rate. Combination treatments with nivolumab […]

read more

International Kidney Cancer Symposium (IKCS) 2021

The International Kidney Cancer Symposium (IKCS) 2021 took place in North America over the weekend. The following presentations are of interest to kidney cancer patients and their families and are published by UroToday: Award lecture: Dr Brian Lane gave the Andrew C. Novick Award Lecture with a talk focusing on the management of small (T1) […]

read more

Immune cell patterns can help predict if kidney cancer patients will respond to immunotherapy

In a study published in Cancer Cell last week, researchers at the Francis Crick Institute, The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumours that can help predict if patients with kidney cancer will respond to immunotherapy. The scientists looked at 115 tumour samples from 15 people with metastatic clear […]

read more

PARP1 as a potential biomarker for response to immunotherapy

In a recent study, the researchers looked at the RNA in renal cell carcinoma (RCC) tissue samples from patients being treated with immune checkpoint inhibitors (e.g. nivolumab, pembrolizumab, avelumab) to try to identify a biomarker for response to treatment. They found that patients with low levels of a protein-coding gene called PARP1 (poly (ADP-ribose) polymerase […]

read more

SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of the combination of cabozantinib (a vascular endothelial growth factor (VEGF) inhibitor) plus nivolumab (an immunotherapy) for use by NHS Scotland for the treatment of untreated people with advanced renal cell carcinoma (RCC). The approval was based on the results from a phase 3 study, which […]

read more

ESMO 2021: Sarcomatoid and/or rhabdoid RCC treated with immune checkpoint inhibitors after surgery

Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number of cancer cells (tumour burden), reduce the symptoms and immunosuppression caused by the tumour, and prevent complications. Recent studies have questioned the role of cytoreductive nephrectomy for patients with RCC that has spread (metastatic RCC). Metastatic sarcomatoid/rhabdoid clear cell RCC is an aggressive type of RCC that responds […]

read more

Outcomes and side effects after first-line treatment with combination therapies for kidney cancer

This report looked at the results from 4 studies comparing sunitinib with various immunotherapy combinations: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib. Overall survival time, time to when the cancer started growing again and the treatment stopped working (progression-free survival), response to treatment in terms of the cancer getting smaller, and side effects to treatment were all […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer

Non-clear cell RCC is about 20-25% of all RCC diagnoses and usually has worse survival outcomes than clear cell RCC. Both cabozantinib and immune checkpoint inhibitors have been shown to help patients with non-clear cell RCC. KEYNOTE-427 is a phase 2 study that looked at the treatment of people with RCC with pembrolizumab as their […]

read more

ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer

KEYNOTE-427 is an open-label, single-arm, phase II study to look at the effectiveness of pembrolizumab as a first-line treatment for people with advanced clear cell RCC. At ESMO this year, updated efficacy, and safety results after a minimum follow-up of 41 months were presented. This study looked at the treatment of people with RCC with […]

read more

Camrelizumab plus famitinib in patients with advanced or metastatic kidney cancer

An ongoing phase 2 study of a combination of two new medicines, camrelizumab (an immune checkpoint inhibitor) and famitinib (a novel tyrosine kinase inhibitor that targets a number of kinases) is looking at the safety and effectiveness of this combination in people with advanced or metastatic clear cell renal cell carcinoma (RCC). Previously treated people […]

read more
Showing 1 to 10 of 303 results
  TOP